R&D Supporting Pilot Study for the Assessment of the Safety and Effectiveness of the ProVATE (ProTIPI) Vaginal Pessary

December 30, 2015 updated by: ConTIPI Medical

Pilot Study for the Evaluation of the ProVATE (ProTIPI) Pessary Designs in the Temporary Management of Pelvic Organ Prolapse (POP) in Women

The study includes five (5) main stages: Screening, Enrollment, Size fitting, Usage and Termination.

Subject screening will be held during visit one (1) and visit two (2) at the clinic.

Initiation and Size fitting:

All eligible subjects will undergo size fitting by a gynecologist / urogynecologist, during visit 2, to find the suitable size for her. The subject will use the ProVATE device of the chosen size at the clinic vicinity for about one (1) hour and for 40-80 hours at her home environment, to confirm that the chosen size is appropriate for the user. Each usage will be followed by a vaginal examination. In case the investigator will determine that the subject should be fitted with a different size of the ProVATE device the subject will repeat this stage with a different device size until the suitable size is confirmed by the investigator.

Usage:

The subject will use the ProVATE device for at least 28 days during a 45 days period, at her home environment, and fill a usage diary. Each device will be used for at least 24 hours. At least one (1) follow-up phone call will be held with the subject per a week. After 14 usage days or following at least two (2) usages (the latest of them) the subject will be scheduled for vaginal examination at the clinic (visit four (4)).

End Of Use At the end of use the subject will return to the clinic (visit five (5)) for a vaginal examination and additional activities.

The following questionnaires will be filled at baseline and end of study: Quality Of Life (QoL) and POP symptoms. Satisfaction and Ease Of Use questionnaires will be filled at the end of use (visit 5) Up to four (4) ProVATE device models will be tested in this study.

Study Overview

Status

Unknown

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Herzliya, Israel
        • Site 01
      • Herzliya, Israel
        • Site 02
      • ramat HaSharon, Israel
        • Site 03

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Females aged 21-80 years
  • Ability to use both hands and insert a device into the vagina
  • Ability to attend the study site as explained by the investigator
  • A symptomatic sensation of vaginal prolapse
  • The subject has the ability to understand the nature of the study and sign the informed consent
  • On examination, the presence of a vaginal wall prolapse of one or more sites
  • On examination, POP-Q grade 2 - 4 POP is demonstrated
  • A 61-91 mm pessary is well fitted
  • A 61-91 mm pessary is well retained

Exclusion Criteria:

  • Previous inability to accommodate with tampons or vaginal pessaries
  • Subject is currently participating in another clinical study which may directly or indirectly affect the results of this study
  • Co-morbid condition(s) or severe systemic disease that could limit the subject 's ability to participate in the study, or impact the scientific integrity of the study
  • Subject is pregnant, or suspected to be pregnant or is planning to be pregnant during the course of the study
  • Abnormal vaginal bleeding in the past 6 months
  • Previous vaginal surgery during the last 3 months
  • A severely atrophic vagina
  • Existing vaginal or vulvar laceration
  • Symptomatic vaginal infection as determined by physical examination and lab results
  • Symptomatic urinary tract infection as determined by physical examination and lab results
  • Recurrent urinary tract infections
  • Abnormal cervical cytology

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ProVATE vaginal pessary
The ProVATE device is a disposable, single-use, vaginal pessary for the management of Pelvic Organ Prolapse ("POP"). The ProVATE device is similar to other ring pessaries currently on the market. Its features allow for easy and comfortable insertion and removal by the user herself at her home environment. The ProVATE device is provided in six (6) different sizes and is intended for prescription use only.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Degree of prolapse and POP symptoms following ProVATE device insertion, compared to the degree of prolapse prior to the insertion of the ProVATE device (by vaginal examination)
Time Frame: At day 1 - baseline, and following at least 28 and up to 45 days of using the ProVATE vaginal pessary
At day 1 - baseline, and following at least 28 and up to 45 days of using the ProVATE vaginal pessary

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2014

Primary Completion (Anticipated)

September 1, 2016

Study Completion (Anticipated)

September 1, 2016

Study Registration Dates

First Submitted

September 8, 2014

First Submitted That Met QC Criteria

September 10, 2014

First Posted (Estimate)

September 12, 2014

Study Record Updates

Last Update Posted (Estimate)

December 31, 2015

Last Update Submitted That Met QC Criteria

December 30, 2015

Last Verified

December 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • ProVATE PT 103

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pelvic Organ Prolapse

Clinical Trials on ProVATE vaginal pessary

3
Subscribe